Table 3. Response to therapy in intermediate risk patients (n = 58) during the first 2 years of follow-up.
| Intermediate risk patients | Excellent (n = 46) | Indeterminate (n = 9) | Biochemical incomplete (n = 2) | Structural incomplete (n = 1) | p-value |
|---|---|---|---|---|---|
| Age (years) | 42 (18-69) | 36 (34-43) | 34.5 (19-50) | 59 | 0.16 |
| Gender-female | 91.9% (42) | 66.6% (n = 6) | 100% (n = 2) | 100% (n = 1) | 0.48 |
| Histology | |||||
| Papillary thyroid cancer | 97.8% (n = 45) | 100% (n = 9) | 100% (n = 2) | 100% (n = 1) | 0.96 |
| Post operative non stimulated Tg | < 0.1 (< 0.1-0.5) | 0.1 (< 0.1-0.2) | 1.4 | 3 | < 0.01 |
| ETE | 69.6% (n = 32) | 55.5% (n = 5) | 100% (n = 2) | 100% (n = 1) | 0.89 |
| Size (cm) | 2.1 (1.0-4.7) | 2.3 (2.1-3.0) | 1.5 (0.6-2.4) | 1.4 | 0.92 |
| N1 | 37% (n = 17) | 22.2% (n = 2) | 50% (n = 1) | 0% | 0.80 |
| RRA | 65.2% (n = 30) | 44.4% (n = 4) | 50% (n = 1) | 100% (n = 1) | 0.66 |
Data are presented as percentage (number) or median (range). Tg: thyroglobulin; N1: lymph node metastases; RRA: radioiodine.